Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592539 | 0.89 | MAPT (0.58) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL3549893 | 0.87 | MAPT (0.60) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Nitric Acid SCHEMBL2075593 | 0.84 | SIRT6 (0.54) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Nitric Acid SCHEMBL2075754 | 0.81 | MAPT (0.64) | MAPTNPC1RAB9AALDH1A1POLB | |
| SCHEMBL17777345 | 0.79 | MAPT (0.51) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28786813 | 0.79 | MAPT (0.65) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19371386 | 0.78 | MAPT (0.50) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Nitric Acid SCHEMBL2073517 | 0.77 | MAPT (0.54) | MAPTSMN1; SMN2ALDH1A1HDAC8HDAC6 | |
| SCHEMBL4166259 | 0.76 | MAPT (0.61) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4172379 | 0.75 | MAPT (0.50) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005052147-A2 | METHOD OF SCREENING FOR A MODULATOR OF CDK4 | CYCLACEL LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005005438-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES | CYCLACEL LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | MAPT 1359/4885NPC1 1884/4885RAB9A 1753/4885 |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | MAPT 3073/4885NPC1 3120/4885RAB9A 3945/4885 |
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | MAPT 1954/4885NPC1 3230/4885RAB9A 3043/4885 |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | MAPT 1185/4885NPC1 1235/4885RAB9A 2691/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | MAPT 3079/4885NPC1 3160/4885RAB9A 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.